Cancer refers to any one of a large number of diseases characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue. Cancer can spread throughout your body. Normally cells divide and increase in a strictly regulated process called mitosis and also they die through a mechanism called apoptosis or programmed cell death. All these are controlled by the DNA in the cells. But when there is a damage to the DNA where this processes cannot be controlled it can lead to cancer.

Conventional treatment modalities concentrate on destroying the cancerous cells of the body either by surgery, cytotoxic chemotherapy or by very high frequency ionising radiation.

Unfortunately conventional treatments have serious side effects that can lead to the death of the patient. Regarding efficacy a study appeared in the respected Clinical Oncology in 2004 states that Cytotoxic Chemotherapy improves the 5 year survival rates by only 2.1% in the USA and 2.3% in Australia or roughly improves it from 60% to 62 %. The completed report can be accessed below. There are significant side effects such as hair loss, nausea, vomiting, severe pain etc.

In many cases these therapies cannot destroy he cancerous cells completely and remaining cells become more tolerant to the therapies and start metastasing to different parts of the body.

Click on the article which appeared in Fortune magazine to see why despite the fact that billions of dollars are spent on the war on cancer and still we are losing it.

RFQMR technology utilizes a totally different approach compared to conventional cancer treatments. Instead of the very high frequency ionising radiation used in radiotherapy RFQMR uses radio or sub-radio frequency, low power, non-ionising, non thermal electromagnetic waves.

The main concern of the therapy is not the immediate destruction of the cancer cells, but rather with the help of the small amount of energy provided to the cell to stop the DNA’s uncontrolled mitosis, put the cell in a vegetative state and in time through apoptosis mechanism let the body get rid of the cancerous cells in a controlled fashion.

Several clinical studies shows that changes in the transmembrane potential of the cells can have dramatic effects on the cell parameters including the ion concentration and more data can be obtained in the Scientific Research Section. RFQMR application helps to increase the transmembrane potential of the cancerous cells from the problematic -20 mV to the healthy -90 mV range. It is believed that the p53 proteins are activated and the uncontrolled mitosis of the cell comes to a halt by the RFQMR application.   

A phase 1 clinical study has been held at the Institute of Aerospace Medicine in Bangalore India between 2004 and 2006 on more than 100 terminal cancer patients. All patients were undergone all possible conventional interventions such as chemo, radiotherapy or surgery prior to RFQMR and yet the disease cannot be controlled and they are supposed to die within a few days to few months due to cancer. Out of such patients :

• There is a 90% symptomatic relief (such as ease of pain, stop using pain killers, no more weight loss etc)
• In most of the patients the tumor progression is stopped or reversed
• More than 60% survived more than 1 year
• More than 35 % went back to normal lives and living disease free for 2 years
  

As all of those patients are supposed to be dead by now, the outcomes of the Cytotron therapy is outstanding. It is believed that in patients who are in terminal situation (in better overall condition, with stronger immune system and was not subject to the toxic conventional therapies with side effects) the efficacy of Cytotron will be even more pronounced.

ABSTRACT:
Aims: The debate on the funding and availability of cytotoxic drugs raises questions about the contribution of curative or adjuvant cytotoxic chemotherapy to survival in adult cancer patients.
Materials and methods: We undertook a literature search for randomised clinical trials reporting a 5-year survival benefit attributable solely to cytotoxic chemotherapy in adult malignancies. The total number of newly diagnosed cancer patients for 22 major adult malignancies was determined from cancer registry data in Australia and from the Surveillance Epidemiology and End Results data in the USA for 1998. For each malignancy, the absolute number to benefit was the product of (a) the total number of persons with that malignancy; (b) the proportion or subgroup(s) of that malignancy showing a benefit; and (c) the percentage increase in 5-year survival due solely to cytotoxic chemotherapy. The overall contribution was the sum total of the absolute numbers showing a 5-year survival benefit expressed as a percentage of the total number for the 22 malignancies.
Results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.
Conclusion: As the 5-year relative survival rate for cancer in Australia is now over 60%, it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required. Morgan, G. et al. (2004). Clinical Oncology 16, 549e560

ABSTRACT:
Context:  Increased 5-year survival for cancer patients is generally inferred to mean that cancer treatment has improved and that fewer patients die of cancer. Increased 5-year survival, however, may also reflect changes in diagnosis: finding more people with early-stage cancer, including some who would never have become symptomatic from their cancer.

Objective:  To determine the relationship over time between 5-year cancer survival and 2 other measures of cancer burden, mortality and incidence.

Design and Setting:  Using population-based statistics reported by the National Cancer Institute Surveillance, Epidemiology, and End Results Program, we calculated the change in 5-year survival from 1950 to 1995 for the 20 most common solid tumor types. Using the tumor as the unit of analysis, we correlated changes in 5-year survival with changes in mortality and incidence.

Main Outcome Measure:  The association between changes in 5-year survival and changes in mortality and incidence measured using simple correlation coefficients (Pearson and Spearman).

Results:  From 1950 to 1995, there was an increase in 5-year survival for each of the 20 tumor types. The absolute increase in 5-year survival ranged from 3% (pancreatic cancer) to 50% (prostate cancer). During the same period, mortality rates declined for 12 types of cancer and increased for the remaining 8 types. There was little correlation between the change in 5-year survival for a specific tumor and the change in tumor-related mortality (Pearson r=.00; Spearman r=-.07). On the other hand, the change in 5-year survival was positively correlated with the change in the tumor incidence rate (Pearson r=+.49; Spearman r=+.37).

Conclusion:  Although 5-year survival is a valid measure for comparing cancer therapies in a randomized trial, our analysis shows that changes in 5-year survival over time bear little relationship to changes in cancer mortality. Instead, they appear primarily related to changing patterns of diagnosis.

Table 2 :  Impact of cytotoxic chemotherapy on 5-year survival in American adults